| MARUVADA R, ZHU L K, PEARCE D, et al. Cryptococcus Neoformansphospholipase B1 Activates Host Cell Rac1 for Traversal across the Blood-brain Barrier[J]. Cellular Microbiology, 2012, 14(10): 1544-1553. |
| EISENMAN H C, CHOW S K, TSÉ K K, et al. The effect of L-DOPA on Cryptococcus Neoformans Growth and Gene Expression[J]. Virulence, 2011, 2(4): 329-336. |
| SOUZA L K H, COSTA C R, DE FATIMA LISBOA FERNANDES O, et al. Clinical and Microbiological Features of Cryptococcal Meningitis[J]. Revista Da Sociedade Brasileira De Medicina Tropical, 2013, 46(3): 343-347. |
| XU L J, GUO Y Z, ZHAO Y Z, et al. Chemokine and Cytokine Cascade Caused by Skewing of the Th1-Th2 Balance is Associated with High Intracranial Pressure in HIV-Associated Cryptococcal Meningitis[J]. Mediators of Inflammation, 2019, 2019: 1-9. |
| JONG A Y, WU C H, JIANG S B, et al. HIV-1 Gp41 Ectodomain Enhances Cryptococcus Neoformans Binding to HBMEC[J]. Biochemical and Biophysical Research Communications, 2007,356(4): 899-905. |
| SHENG M F S Y S. Gp120 Activates Children's Brain Endothelial Cells Via CD4[J]. Journal of Neurovirology, 2001, 7(2): 125-134. |
| 龙敏, 曹虹, Ambrose Jong. HIV-1gp41胞外域对新生隐球菌致人脑微血管内皮细胞骨架改变的影响[J].南方医科大学学报, 2011, 31(3): 478-481. |
| RAJASINGHAM R, SMITH R M, PARK B J, et al. Global Burden of Disease of HIV-associated Cryptococcal Meningitis: an Updated Analysis[J]. The Lancet Infectious Diseases, 2017, 17(8): 873-881. |
| FANG W, FA Z Z, LIAO W Q. Epidemiology of Cryptococcus and Cryptococcosis in China[J]. Fungal Genetics and Biology, 2015, 78: 7-15. |
| 鲁雁秋, 黄晓婕, 刘敏, 等.重庆地区499例艾滋病合并中枢神经系统感染患者的疾病谱及预后影响因素分析[J].中华传染病杂志, 2018, 36(2): 65-8. |
| 鲁雁秋, 黄晓婕, 吴玉珊, 等. 203例艾滋病合并新型隐球菌性脑膜炎患者预后影响因素研究[J].中华神经医学杂志, 2018, 17(4): 397-401. |
| PARK B J, WANNEMUEHLER K A, MARSTON B J, et al. Estimation of the Current Global Burden of Cryptococcal Meningitis among Persons Living with HIV/AIDS[J]. AIDS, 2009, 23(4): 525-530. |
| FRENCH N, GRAY K, WATERA C, et al. Cryptococcal Infection in a Cohort of HIV-1-infected Ugandan Adults[J]. AIDS, 2002, 16(7): 1031-1038. |
| LAZERA M S, CAVALCANTI M A S, LONDERO A T, et al. Possible Primary Ecological Niche of Cryptococcus Neoformans[J]. Medical Mycology, 2000, 38(5): 379-383. |
| 林苏, 张彦亮, 邵凌云, 等.隐球菌性脑膜炎并发颅神经损伤的危险因素及预后因素分析[J].中华传染病杂志, 2013(3): 155-159. |
| TUGUME L, RHEIN J, HULLSIEK K H, et al. HIV-Associated Cryptococcal Meningitis Occurring at Relatively Higher CD4 Counts[J]. The Journal of Infectious Diseases, 2019,219(6): 877-883. |
| KIERTIBURANAKUL S, SUNGKANUPARPH S, BUABUT B, et al. Cryptococcuria as a Manifestation of Disseminated Cryptococcosis and Isolated Urinary Tract Infection[J]. Japanese Journal of Infectious Diseases, 2004, 57(5): 203-205. |
| BARITEAU J T, WARYASZ G R, MCDONNELL M, et al. Fungal Osteomyelitis and Septic Arthritis[J]. Journal of the American Academy of Orthopaedic Surgeons, 2014, 22(6): 390-401. |
| TAPPERO J W, PERKINS B A, WENGER J D, et al. Cutaneous Manifestations of Opportunistic Infections in Patients Infected with Human Immunodeficiency Virus[J]. Clinical Microbiology Reviews, 1995, 8(3): 440-450. |
| 吴俊.肺隐球菌病(PC)肺部CT增强扫描影像表现及临床病理分析[J].中国CT和MRI杂志, 2016, 14(1): 59-61. |
| ANTINORI S. New Insights into HIV/AIDS-Associated Cryptococcosis[J]. Isrn Aids, 2013, 2013: 1-22. |
| World Health Organization. Rapid Advice: Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-Infected Adults, Adolescents and Children: December 2011[J]. International Journal of Modern Physics C, 2011, 2(1): 391-394. |
| SOUTHERN AFRICAN HIV CLINICIANS SOCIETY T. Guideline for the Prevention, Diagnosis and Management of Cryptococcal Meningitis among HIV-infected Persons: 2013 Update[J]. Southern African Journal of HIV Medicine, 2013, 14(2): 76-86. |
| LINDSLEY M D, MEKHA N, BAGGETT H C, et al. Evaluation of a Newly Developed Lateral Flow Immunoassay for the Diagnosis of Cryptococcosis[J]. Clinical Infectious Diseases, 2011, 53(4): 321-325. |
| HUANG H R, FAN L C, RAJBANSHI B, et al. Evaluation of a New Cryptococcal Antigen Lateral Flow Immunoassay in Serum, Cerebrospinal Fluid and Urine for the Diagnosis of Cryptococcosis: a Meta-Analysis and Systematic Review[J]. PLoS One, 2015, 10(5): e0127117. DOI: 10. 1371/journal. pone. 0127117. |
| WILLIAMS D A, KⅡZA T, KWIZERA R, et al. Evaluation of Fingerstick Cryptococcal Antigen Lateral Flow Assay in HIV-Infected Persons: a Diagnostic Accuracy Study: Figure 1[J]. Clinical Infectious Diseases, 2015, 61(3): 464-467. |
| BABADY N E, BESTROM J E, JESPERSEN D J, et al. Evaluation of Three Commercial Latex Agglutination Kits and a Commercial Enzyme Immunoassay for the Detection of Cryptococcal Antigen[J]. Medical Mycology, 2009, 47(3): 336-338. |
| KEDZIERSKA A, KOCHAN P, PIETRZYK A, et al. Current Status of Fungal Cell Wall Components in the Immunodiagnostics of Invasive Fungal Infections in Humans: Galactomannan, Mannan and (1→3)-β-D-glucan Antigens[J]. European Journal of Clinical Microbiology & Infectious Diseases, 2007, 26(11): 755-766. |
| KOURBETI I S, MYLONAKIS E. Fungal Central Nervous System Infections: Prevalence and Diagnosis[J]. Expert Review of Anti-Infective Therapy, 2014, 12(2): 265-273. |
| MAZIARZ E K, PERFECT J R. Cryptococcosis[J]. Infectious Disease Clinics of North America, 2016, 30(1): 179-206. |
| 李皇, 卢平宣.真菌感染实验室诊断技术进展[J].河北联合大学学报(医学版), 2014, 16(1): 36-38. |
| 陈莉萍.实体器官移植术后隐球菌病的研究进展[J].器官移植, 2018, 9(1): 9-15. |
| 黄铭珊, 金霆.探讨实时荧光定量PCR法检测血液新生隐球菌的临床意义[J].实用检验医师杂志, 2015, 7(1): 28-31. |
| DOU H T, XU Y C, WANG H Z, et al. Molecular Epidemiology of Cryptococcus Neoformans and Cryptococcus Gattii in China between 2007 and 2013 Using Multilocus Sequence Typing and the DiversiLab System[J]. European Journal of Clinical Microbiology & Infectious Diseases, 2015, 34(4): 753-762. |
| HERKERT P F, MEIS J F, LUCCA DE OLIVEIRA SALVADOR G, et al. Molecular Characterization and Antifungal Susceptibility Testing of Cryptococcus Neoformans Sensu Stricto from Southern Brazil[J]. Journal of Medical Microbiology, 2018, 67(4): 560-569. |
| KOHNO S, KAKEYA H, IZUMIKAWA K, et al. Clinical Features of Pulmonary Cryptococcosis in non-HIV Patients in Japan[J]. Journal of Infection and Chemotherapy, 2015, 21(1): 23-30. |
| 吴玉珊, 刘敏, 鲁雁秋, 等.艾滋病/隐球菌性脑膜炎与艾滋病/结核性脑膜炎临床特征的差异性研究[J].中国感染与化疗杂志, 2019, 19(6): 590-593. |
| CALEB S, SCHLEISS M R, BANGDIWALA A S, et al. Cytomegalovirus Viremia Associated with Increased Mortality in Cryptococcal Meningitis in Sub-Saharan Africa[J]. Clinical Infectious Diseases, 2019(9): 864. |
| 王珍燕, 沈银忠, 刘莉, 等. 35例艾滋病患者曲霉菌感染与定植临床特征分析[J].中华传染病杂志, 2018, 36(8): 485-489. |
| JARVIS J N, MEINTJES G, WILLIAMS A, et al. Adult Meningitis in a Setting of High HIV and TB Prevalence: Findings from 4961 Suspected Cases[J]. BMC Infectious Diseases, 2010, 10: 67. |
| CORRÊA PINHEIRO M, DOS REIS D S T, DE BRITO M T F M, et al. Cryptococcosis in the Amazon: a Current Overview and Future Perspectives[J]. Acta Tropica, 2019,197: 105023. |
| FORD N, SHUBBER Z, JARVIS J N, et al. CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-analysis[J]. Clin Infect Dis. 2018, 66(S2): 152-159. |
| The National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for The Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-Infected Adults, Adolescents and Children: Supplement to the 2016 Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection, [EB/OL]. (2019/6/26)[2020/5/16]. https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/322/toxoplasma-gondii-encephalitis. |
| SRICHATRAPIMUK S, SUNGKANUPARPH S. Integrated Therapy for HIV and Cryptococcosis[J]. AIDS Research and Therapy, 2016, 13: 42. |
| RAJASINGHAM R, BOULWARE D R. Cryptococcal Antigen Screening and Preemptive Treatment-How can we Improve Survival?[J]. Clinical Infectious Diseases, 2020, 70(8): 1691-1694. |
| NALINTYA E, MEYA D B, LOFGREN S, et al. A Prospective Evaluation of a Multisite Cryptococcal Screening and Treatment Program in HIV Clinics in Uganda[J]. JAIDS Journal of Acquired Immune Deficiency Syndromes, 2018, 78(2): 231-238. |
| YAO Z W, LU X, SHEN C, et al. Comparison of Flucytosine and Fluconazole Combined with Amphotericin B for the Treatment of HIV-associated Cryptococcal Meningitis: a Systematic Review and Meta-analysis[J]. European Journal of Clinical Microbiology & Infectious Diseases, 2014, 33(8): 1339-1344. |
| LOYSE A, BICANIC T, JARVIS J N. Combination Antifungal Therapy for Cryptococcal Meningitis[J]. The New England Journal of Medicine, 2013,368(26): 2522-2523. |
| TENFORDE M W, GERTZ A M. Mortality from Hiv-Associated Meningitis in Sub-Saharan Africa: A Systematic Review and Meta-Analysis[J]. J Int AIDS Soc, 2020, 23(1): 25416-25428. |
| XU L, TAO R, WU J, et al. Short-Course Rather Than Low-Dose Amphotericin B May Exert Potential Influence on Mortality in Cryptococcal Meningitis Patients Treated With Amphotericin B Plus Flucytosine Alone or in Combination With Fluconazole[J]. Frontiers in microbiology, 2019, 10: 2082-2110. |
| HAMILL R J, SOBEL J D, EL-SADR W, et al. Comparison of 2 Doses of Liposomal Amphotericin B and Conventional Amphotericin B Deoxycholate for Treatment of AIDS-Associated Acute Cryptococcal Meningitis: a Randomized, Double-Blind Clinical Trial of Efficacy and Safety[J]. Clinical Infectious Diseases, 2010, 51(2): 225-232. |
| PAPPAS P G, CHETCHOTISAKD P, LARSEN R A, et al. A Phase Ⅱ Randomized Trial of Amphotericin B Alone or Combined with Fluconazole in the Treatment of HIV-Associated Cryptococcal Meningitis[J]. Clinical Infectious Diseases, 2009, 48(12): 1775-1783. |
| YAO Y, ZHANG J T, YAN B, et al. Voriconazole: a Novel Treatment Option for Cryptococcal Meningitis[J]. Infectious Diseases, 2015, 47(10): 694-700. |
| GAZZONI A F, CAPILLA J, MAYAYO E, et al. Efficacy of Intrathecal Administration of Liposomal Amphotericin B Combined with Voriconazole in a Murine Model of Cryptococcal Meningitis[J]. International Journal of Antimicrobial Agents, 2012, 39(3): 223-227. |
| 陶然, 师金川, 郭永征, 等.两性霉素B去氧胆酸盐、两性霉素B脂质体和伏立康唑诱导治疗HIV相关性隐球菌脑膜炎的效果比较[J].新发传染病电子杂志, 2019(2): 97-102. |
| TREVIÑO-RANGEL R J, VILLANUEVA-LOZANO H, HERNÁNDEZ-RODRÍGUEZ P, et al. Activity of Sertraline againstCryptococcus Neoformans: In Vitroandin Vivoassays[J]. Medical Mycology, 2016, 54(3): 280-286. |
| VILLANUEVA-LOZANO H, TREVIÑO-RANGEL R J, GONZÁLEZ G M, et al. Clinical Evaluation of the Antifungal Effect of Sertraline in the Treatment of Cryptococcal Meningitis in HIV Patients: a Single Mexican Center Experience[J]. Infection, 2018, 46(1): 25-30. |
| HAI T P, VAN A D, NGAN N T T, et al. The Combination of Tamoxifen with Amphotericin B, but not with Fluconazole, Has Synergistic Activity Against the Majority of Clinical Isolates of Cryptococcus Neoformans[J]. Mycoses, 2019: myc. 12955. |
| GARVEY E P, SHARP A D, WARN P A, et al. The Novel Fungal CYP51 Inhibitor VT-1598 is Efficacious Alone and in Combination with Liposomal Amphotericin B in a Murine Model of Cryptococcal Meningitis[J]. Journal of Antimicrobial Chemotherapy, 2018, 73(10): 2815-2822. |
| WIEDERHOLD N P, NAJVAR L K, GARVEY E P, et al. The Fungal Cyp51 Inhibitor VT-1129 Is Efficacious in an Experimental Model of Cryptococcal Meningitis[J]. Antimicrobial agents and chemotherapy, 2018, 62(9): 1071-1088. |
| WIEDERHOLD N P, XU X, WANG A, et al. In Vivo Efficacy of VT-1129 against Experimental Cryptococcal Meningitis with the Use of a Loading Dose-Maintenance Dose Administration Strategy[J]. Antimicrobial Agents and Chemotherapy, 2018, 62(11): 1315-1332. |
| VIBHAGOOL A, SUNGKANUPARPH S, MOOTSIKAPUN P, et al. Discontinuation of Secondary Prophylaxis for Cryptococcal Meningitis in Human Immunodeficiency Virus-Infected Patients Treated with Highly Active Antiretroviral Therapy: a Prospective, Multicenter, Randomized Study[J]. Clinical Infectious Diseases, 2003, 36(10): 1329-1331. |
| NEWTON P N, THAI L H, TIP N Q, et al. A Randomized, Double-Blind, Placebo-Controlled Trial of Acetazolamide for the Treatment of Elevated Intracranial Pressure in Cryptococcal Meningitis[J]. Clinical Infectious Diseases, 2002, 35(6): 769-772. |
| 胡志亮, 郑立冲, 池云, 等.积极控制颅内高压逆转HIV相关隐球菌性脑膜炎所致严重视力损害一例及文献复习[J].中华实验和临床感染病杂志(电子版), 2017, 11(6): 617-621. |
| BEARDSLEY J, WOLBERS M, KIBENGO F M, et al. Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis[J]. New England Journal of Medicine, 2016,374(6): 542-554. |
| ROLFES M A, HULLSIEK K H, RHEIN J, et al. The Effect of Therapeutic Lumbar Punctures on Acute Mortality from Cryptococcal Meningitis[J]. Clinical Infectious Diseases, 2014, 59(11): 1607-1614. |
| 方凯, 陈文焰, 梁亚明, 等.腰大池引流结合鞘内注射治疗脑出血侧脑室外引流术后颅内感染的效果观察[J].临床医学工程, 2019, 26(11): 1513-1514. |
| DEY M, JAFFE J, STADNIK A, et al. External Ventricular Drainage for Intraventricular Hemorrhage[J]. Current Neurology and Neuroscience Reports, 2012, 12(1): 24-33. |
| SONABEND A M, KORENFELD Y, CRISMAN C, et al. Prevention of Ventriculostomy-Related Infections with Prophylactic Antibiotics and Antibiotic-Coated External Ventricular Drains: a Systematic Review[J]. Neurosurgery, 2011, 68(4): 996-1005. |
| 李培亮, 梁庭毓, 梁博, 等.外科治疗艾滋病合并新型隐球菌脑膜炎所致颅内高压的疗效[J].中华神经外科杂志, 2019, 35(11): 1152-1524. |
| CHERIAN J, ATMAR R L, GOPINATH S P. Shunting in Cryptococcal Meningitis[J]. Journal of Neurosurgery, 2016,125(1): 177-186. |
| LIU Y, PENG X H, WENG W Z, et al. Efficacy of Ventriculoperitoneal Shunting in Patients with Cryptococcal Meningitis with Intracranial Hypertension[J]. International Journal of Infectious Diseases, 2019, 88: 102-109. |
| LIU L, ZHANG R F, TANG Y, et al. The Use of Ventriculoperitoneal Shunts for Uncontrollable Intracranial Hypertension in Patients with HIV-associated Cryptococcal Meningitis with or without Hydrocephalus[J]. BioScience Trends, 2014, 8(6): 327-332. |
| 鲁雁秋, 邱丹, 陈耀凯.艾滋病合并新型隐球菌性脑膜炎患者的综合治疗[J].中华临床感染病杂志, 2018(2): 156-160. |
| OLIVEIRA F T M D. Central Nervous System Antiretroviral High Penetration Therapy[J]. Journal of AIDS & Clinical Research, 2015, 6(12): 134-136. |
| BOULWARE D R, MEYA D B, MUZOORA C, et al. Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis[J]. New England Journal of Medicine, 2014,370(26): 2487-2498. |
| ESHUN-WILSON I, OKWEN M P, RICHARDSON M, et al. Early Versus Delayed Antiretroviral Treatment in HIV-Positive People with Cryptococcal Meningitis[J]. The Cochrane Database of Systematic Reviews, 2018, 7(7): 9012-9034. |
| JARVIS J N, BICANIC T, LOYSE A, et al. Determinants of Mortality in a Combined Cohort of 501 Patients with HIV-Associated Cryptococcal Meningitis: Implications for Improving Outcomes[J]. Clinical Infectious Diseases, 2014, 58(5): 736-745. |
| AK M, BD M, H M-K, et al. Challenges in Diagnosis and Management of Cryptococcal Immune Reconstitution Inflammatory Syndrome (IRIS) in Resource Limited Settings[J]. African health sciences, 2012, 12(2): 226-230. |
| MANFREDI R, PIERI F, PILERI S A, et al. The Changing Face of AIDS-related Opportunism: Cryptococcosis in the Highly Active Antiretroviral Therapy (HAART) Era. Case Reports and Literature Review[J]. Mycopathologia, 1999,148(2): 73-78. |
| NARAYANAN S, BANERJEE C, HOLT P A. Cryptococcal Immune Reconstitution Syndrome during Steroid Withdrawal Treated with Hydroxychloroquine[J]. International Journal of Infectious Diseases, 2011, 15(1): 70-73. |
| BRUNEL A S, REYNES J, TUAILLON E, et al. Thalidomide for Steroid-dependent Immune Reconstitution Inflammatory Syndromes during AIDS[J]. AIDS, 2012, 26(16): 2110-2112. |
| SITAPATI A M, KAO C L, CACHAY E R, et al. Treatment of HIV-related Inflammatory Cerebral Cryptococcoma with Adalimumab[J]. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America, 2010, 50(2): 7-10. |
| PERFECT J R, DISMUKES W E, DROMER F, et al. Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America[J]. Clinical Infectious Diseases, 2010, 50(3): 291-322. |
| NAYAK S U, TALWANI R, GILLIAM B, et al. Cryptococcal Meningitis in an HIV-Positive Pregnant Woman[J]. Journal of the International Association of Physicians in AIDS Care, 2011, 10(2): 79-82. |
| PASTICK K A, NALINTYA E, TUGUME L, et al. Cryptococcosis in Pregnancy and the Postpartum Period: Case Series and Systematic Review with Recommendations for Management[J]. Medical Mycology, 2020, 58(3): 282-292. |